146 stories from 24 sources
The week in Medicine and Healthcare
Click on a headline to see stories that shaped it.
Threads
8 threads
GLP-1 demand expanded rapidly through Medicare while Lilly gained ground against Novo in oral and injectable competition. The week also added evidence that stopping treatment may carry cardiovascular risk, highlighted lawsuits and pediatric nutritional concerns, and pushed manufacturers toward new dosing and delivery strategies.
Measles reached its worst US severity in decades as Pennsylvania used door-to-door vaccination outreach after deaths. Disputed federal vaccine messaging and continuing arguments over Covid, trust, and measles mortality made confidence and communication central to containment.
Federal Medicaid cuts, work-documentation rules, and ACA enrollment cancellations combined to threaten coverage for millions. The changes shift more pressure onto states and could make administrative proof a new barrier to care.
Ebola spread into additional health zones in the Democratic Republic of the Congo and prompted warnings for 10 neighboring countries. The expansion turned containment into a broader cross-border surveillance and response challenge.
Warnings that reduced US health assistance could reverse decades of HIV progress in Africa made funding instability a direct treatment and prevention threat. The potential damage extends beyond budgets because disrupted services could increase infections.
Federal pressure and court fights led dozens of US hospitals to end or limit gender-affirming care for young people. Patients now face fewer providers, longer waits, and sharply different access depending on location.
Healthcare AI funding and adoption moved beyond documentation into clinical decisions, radiology, charting, and consumer care. Reports of protected-data access and nearly $1 billion in added insurer costs shifted the debate toward oversight, reimbursement, privacy, and accountability.
Proposals to increase political control over NIH grants appeared, then seemed to stall, while the FDA commissioner nominee faced repeated questions about vaccines, abortion medication, and regulatory independence. The week's disputes left the direction of federal scientific oversight unsettled.
Day’s Recap